• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XIAN Zhiran, SUN Chunmeng, LUO Xuefang, ZHONG Wenying. Profiling of genotoxic impurities in a lidocaine hydrochloride injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 466-471. DOI: 10.11665/j.issn.1000-5048.20200412
Citation: XIAN Zhiran, SUN Chunmeng, LUO Xuefang, ZHONG Wenying. Profiling of genotoxic impurities in a lidocaine hydrochloride injection[J]. Journal of China Pharmaceutical University, 2020, 51(4): 466-471. DOI: 10.11665/j.issn.1000-5048.20200412
shu

Profiling of genotoxic impurities in a lidocaine hydrochloride injection

  • 1.

    Drug Quality Research Center, College of Science, China Pharmaceutical University

  • 2.

    School of Pharmacy, China Pharmaceutical University, China

More Information
  • Received Date: March 19, 2020
    Graphical Abstract
    • Abstract

  • This page contains the following errors:

    error on line 1 at column 1: Start tag expected, '<' not found

    Below is a rendering of the page up to the first error.
    • FullText(HTML)
    • References (20)
  • [1]
    Long J, Etxeberria AE, Nand AV, et al. A 3D printed chitosan-pectin hydrogel wound dressing for lidocaine hydrochloride delivery[J]. Mater Sci Eng C Mater Biol Appl,2019,104:109873. doi: 10.1016/j.msec.2019. 109873.
    [2]
    Chen YQ, Hong BH, Yi RZ. HPLC determination of contents and related substances in the tetrodotoxin lidocaine hydrochloride for injection[J]. Chin J Mar Drugs（中国海洋药物）, 2016,35(3): 67-75.
    [3]
    Wang X, Li X, Xiao Y. A novel dispersive liquid-liquid microextraction method with high performance liquid chromatography for detection of 2,6-dimethylaniline in lidocaine hydrochloride injection[J]. Se Pu,2018,36(3): 292-298.doi: 10.3724/SP.J.1123.2017.11049.
    [4]
    Deng ZH, Li AH, Hu WJ. Improvement of quality control of lidocaine hydrochloride injection[J]. J Pharm Pract（药学实践杂志）,2016(1):72-75.doi: 10.3969/j.issn.1006-0111.2016. 01. 019.
    [5]
    Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia: Part 2(中华人民共和国药典:二部) [S]. Beijing: China Medical Science Press,2015:979-980.
    [6]
    European Pharmacopeia 9.0:Volume III（欧洲药典9.0:卷3）[S]. France: European Directorate for the Quality of Medicine & Healthcare,2017:2905-2906.
    [7]
    The United States Pharmacopoeial Convention. United States Pharmacopoeia 40[S]. Rockville: The United States Pharmacopeial Convention,2017:4847-4848.
    [8]
    Yang RY, Yin XL, Liang M, et al. Microscale experimental study on preparation of lidocaine[J]. Guangdong Chem Ind（广东化工）,2010,37 (5):137, 149.doi: 10.3969/j.issn.1007-1865.2010.05.058.
    [9]
    Zhejiang Huineng Biological Co., Ltd. Method for preparing lidocaine hydrochloride：
    201510738390.7[P].2016-02-03.
    [10]
    Bengbu Fengyuan Pharmaceutical Technology Development Co., Ltd. Method for preparing lidocaine：
    201010579590.X[P].2011-05-25.
    [11]
    Li M. Organic Chemistry of Drug Degradation[M]. United Kingdom: CPI Group (UK) Ltd, Croydon, CR04YY, UK,2012.
    [12]
    Li Q, Magers T, King B, et al. Measurement of lidocaine and 2,6-dimethylaniline in minipig plasma, skin, and dermal tapes using UHPLC with electrospray MS/MS[J]. J Chromatogr B Analyt Technol Biomed Life Sci,2018,1087-1088:158-172. doi: 10.1016/j.jchromb.2018.04.030.
    [13]
    Kobets T, Duan JD, Brunnemann KD, et al. DNA-damaging activities of twenty-four structurally diverse unsubstituted and substituted cyclic compounds in embryo-fetal chicken livers[J]. Mutat Res, 2019,844:10-24.doi: 10.1016/j.mrgentox.2019.06.004.
    [14]
    Koujitani T., Yasuhara K., Kobayashi H., et al. Tumor‐promoting activity of 2,6‐dimethylaniline in a two‐stage nasal carcinogenesis model in N‐bis(2‐hydroxypropyl) nitrosamine‐treated rats[J]. Cancer Lett, 1999,142(2):161-171.
    [15]
    The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Trepartite Guideline: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk M7(R1) [S/OL]. (2017-05-01) [2019-01-28]. https://www.ich.org/fileadmin/.
    [16]
    Heewon L. Pharmaceutical industry practices on genotoxic impurities[M]. US: CRC, 2015:87-88.
    [17]
    Andrew T．Genotoxic impurities strategies for identification and control[M]. Canada: John Wiley & Sons, Inc., Hoboken, New Jersey, 2011: 44-46.
    [18]
    Benigni R, Bossa C. Structure alerts for carcinogenicity, and the Salmonella assay system: a novel insight through the chemical relational databases technology[J]. Mutat Res,2008,659(3):248-261. doi: 10.1016/j.mrrev.2008.05.003.
    [19]
    Xia YL, Zhang AJ, Liu JP. Optimization of tiopronin formulation[J]. Centr South Pharm（中南药学）, 2015,13(7):739-740,779.
    [20]
    Lei XX, Wang Y, Zhang JL, et al. Analysis of the addition and measurement of bacteriostatics and antioxidants in injection and eye drops[J]. Mod Chem Res（当代化工研究）,2017 (4):143-144.
    • Related Articles

  • Related Articles

    [1]YE Zhenning, WU Zhenghong, ZHANG Huaqing. Research progress of blood-brain barrier crossing strategies and brain-targeted drug delivery mediated by nano-delivery system[J]. Journal of China Pharmaceutical University, 2024, 55(5): 590-602. DOI: 10.11665/j.issn.1000-5048.2024052202
    [2]LUO Xuelian, WU Chengsheng, ZHA Cheng, LIU Sheng. Research progress and prospects of implantable drug delivery systems for postoperative tumor therapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 538-547. DOI: 10.11665/j.issn.1000-5048.2024040901
    [3]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [4]YU Jiayu, LIN Zezhi, CAO Wei, ZHANG Jianjun, WEI Yuanfeng, GAO Yuan, QIAN Shuai. Research progress of bio-metal organic frameworks in drug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 23-33. DOI: 10.11665/j.issn.1000-5048.20221111003
    [5]ZHOU Yeshu, WANG Yanmei, ZHANG Beiyuan, WU Shuaicong, YANG Lei, YIN Lifang. Research progress of inorganic nanomaterials in drug delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(4): 394-405. DOI: 10.11665/j.issn.1000-5048.20200403
    [6]LI Haoxian, LIN Huaqing, CHEN Jingwen, WANG Liyuan. Research progress of carbon nanomaterials in cancer drug delivery[J]. Journal of China Pharmaceutical University, 2019, 50(1): 100-106. DOI: 10.11665/j.issn.1000-5048.20190114
    [7]FAN Qianqian, XING Lei, QIAO Jianbin, ZHANG Chenglu, JIANG Hulin. Advances in drug delivery systems for the treatment of liver fibrosis[J]. Journal of China Pharmaceutical University, 2018, 49(3): 263-271. DOI: 10.11665/j.issn.1000-5048.20180302
    [8]CHEN Xing, KANG Yang, WU Jun. Advances in biodegradable functional polymers based protein drug delivery system[J]. Journal of China Pharmaceutical University, 2017, 48(2): 142-149. DOI: 10.11665/j.issn.1000-5048.20170203
    [9]WANG Yazhe, ZHOU Jianping, DING Yang, WANG Wei. Advances in research of biomimetic drug delivery systems[J]. Journal of China Pharmaceutical University, 2014, 45(3): 267-273. DOI: 10.11665/j.issn.1000-5048.20140303
    [10]TANG Yue, KE Xue. Advances of mesoporous silica nanoparticles as drug delivery system[J]. Journal of China Pharmaceutical University, 2012, 43(6): 567-572.

  • Cited by

    Periodical cited type(9)

    1. 蔡鸿飞，张琴，关伟键，杨阳，袁诚，许文东. 不同干燥方式对灵芝孢子粉中灵芝孢子油过氧化值的影响. 广东化工. 2024(01): 28-30 .
    2. 林志彬. 灵芝孢子油的药效物质基础研究进展. 菌物研究. 2024(01): 79-87 .
    3. Jianying Liu，Binzhi Zhang，Leqi Wang，Shasha Li，Qinqiang Long，Xue Xiao. Bioactive components, pharmacological properties and underlying mechanism of Ganoderma lucidum spore oil: A review. Chinese Herbal Medicines. 2024(03): 375-391 .
    4. 武美华，张胜男，敬隆鑫，律凤霞. 灵芝的活性成分及其药理作用的研究进展. 中国林副特产. 2023(02): 76-79 .
    5. 夏凤娜，关小莺，陈少丹，陈秋颜，张一帆，杨小兵. 灵芝孢子粉脂质成分HPLC-ELSD指纹图谱构建及含量测定. 食用菌学报. 2023(06): 52-59 .
    6. 井子良，吴纯宇，张慧敏，孙建博. 灵芝孢子油番茄红素复合物的抗肿瘤作用. 现代食品科技. 2022(09): 46-51 .
    7. 李志强，何玉霞. 灵芝多糖对人肺癌A549细胞增殖凋亡的作用. 现代食品科技. 2021(05): 38-42 .
    8. 张琴，李康强，杨阳，张圳，蔡鸿飞，许文东. 不同提取方式的灵芝孢子油品质研究. 广东化工. 2021(11): 48-49 .
    9. 包县峰，徐勇，刘维明，王星丽，孙培龙，张安强. 灵芝孢子粉生物活性成分及药理作用. 食品工业科技. 2020(06): 325-331 .

    Other cited types(6)

Catalog

    Get Citation
    PDF
    XML
    Article views PDF downloads Cited by(15)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：286500

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return